Skip to main content

Table 1 U.S. patient population prevalence estimates for rare genetic disease drug development programs

From: Dose-finding studies in drug development for rare genetic diseases

Patient population size

Number of programs

< 1000

6

1000 to < 10,000

10

10,000 to < 100,000

18

100, 000 to < 200,000

6